<DOC>
	<DOCNO>NCT02250495</DOCNO>
	<brief_summary>The purpose VIBE study evaluate efficacy safety Sympara Therapeutic System treatment hypertension</brief_summary>
	<brief_title>The Sympara VIBE Study Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<criteria>Office systolic blood pressure ≥150mmHg base average three ( 3 ) blood pressure reading measure initial screen visit confirmatory screen visit OR mean daytime systolic blood pressure ≥135mm Hg 24hour Ambulatory Blood Pressure Measurement Receiving adhere appropriate antihypertensive treatment regimen , prescribe physician Minimum six ( 6 ) month history diagnosis treatment hypertension Previous renal denervation carotid barostimulation implant Secondary cause hypertension primary pulmonary hypertension Prior surgery radiation area carotid sinus , presence stent implant carotid artery Known suspect baroreflex failure significant orthostatic hypotension One hospital admission hypertensive crisis within past year History myocardial infarction , fibrillation event , unstable angina pectoris , syncope , transient ischemic attach ( TIA ) cerebrovascular accident within six ( 6 ) month screen period , widespread atherosclerosis document intrasvascular thrombosis unstable plaque Diabetes mellitus ( Type 1 ) Chronic renal disease require dialysis Kidney liver transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>